Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT06313970 Not yet recruiting - Pancreatic Cancer Clinical Trials

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer

NCT ID: NCT06311032 Completed - Clinical trials for Surgery Risk Assessment

Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas

Start date: March 29, 2023
Phase:
Study type: Observational

The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.

NCT ID: NCT06310993 Not yet recruiting - Pancreatic Cancer Clinical Trials

Exercise to Boost Immunity in Advanced Cancer

BICEP
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression

NCT ID: NCT06310902 Recruiting - Clinical trials for Pancreatic Neoplasms

Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients

Start date: March 1, 2024
Phase:
Study type: Observational

Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.

NCT ID: NCT06307080 Recruiting - Pancreatic Cancer Clinical Trials

Clinical Study of Multi-mode Thermal Ablation for the Treatment of Pancreatic Cancer With Liver Metastasis

Start date: October 8, 2023
Phase: N/A
Study type: Interventional

1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.

NCT ID: NCT06291779 Recruiting - Pancreas Cancer Clinical Trials

Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine

Start date: November 30, 2022
Phase:
Study type: Observational [Patient Registry]

- This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine. - It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.

NCT ID: NCT06289803 Recruiting - Pancreatic Cancer Clinical Trials

The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Aim of the study: To evaluate the value of Probe Confocal Laser Endomicroscopy (PCLE) in surgery for pancreatic tumor. Methods: Patients who are diagnosed with pancreatic tumor based on preoperative radiographic findings and will undergo radical resection are included in this clinical study. PCLE will be used in surgery to identify tumor is malignant or not, and surgeons will decide procedures of surgery based on outcomes of PCLE. In this present study, clinical trials will be divided into two phases. In the first phase, based on the definitive postoperative pathologic diagnosis, characteristic imaging structures that were collected by PCLE will be identified and primary diagnostic imaging criteria for pancreatic cancer would be developed. In the second phase, this criterion will be used for rapid intraoperative diagnosis of pancreatic cancer and predicting status of resection margin. In addition, accuracy of PCLE will be verified based on postoperative pathologic reports.

NCT ID: NCT06287749 Not yet recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Start date: March 1, 2024
Phase:
Study type: Observational

The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after 1. curative-intended surgery and 2. adjuvant chemotherapy. FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project

NCT ID: NCT06283576 Enrolling by invitation - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Initial Detection Via Liquid Biopsy

PANCAID
Start date: March 1, 2024
Phase:
Study type: Observational

The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas [N0M0]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).

NCT ID: NCT06282809 Not yet recruiting - Pancreatic Cancer Clinical Trials

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

GANNON
Start date: June 2024
Phase: N/A
Study type: Interventional

The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.